S
Salvador Villà
Researcher at Autonomous University of Barcelona
Publications - 79
Citations - 12144
Salvador Villà is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Radiation therapy & Prostate cancer. The author has an hindex of 34, co-authored 76 publications receiving 10562 citations.
Papers
More filters
Journal ArticleDOI
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp,Monika E. Hegi,Warren P. Mason,Martin J. van den Bent,Martin J.B. Taphoorn,Robert C. Janzer,Samuel K. Ludwin,Anouk Allgeier,Barbara Fisher,Karl Belanger,Peter Hau,Alba A. Brandes,J.M.M. Gijtenbeek,Christine Marosi,Charles J. Vecht,Karima Mokhtari,Pieter Wesseling,Salvador Villà,Elizabeth Eisenhauer,Thierry Gorlia,Michael Weller,Denis Lacombe,J. Gregory Cairncross,René-Olivier Mirimanoff +23 more
TL;DR: Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years.
Journal ArticleDOI
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher,Riccardo Soffietti,Ufuk Abacioglu,Salvador Villà,François Fauchon,Brigitta G. Baumert,L. Fariselli,Tzahala Tzuk-Shina,Rolf-Dieter Kortmann,Christian Carrie,Mohamed Ben Hassel,Mauri Kouri,Egils Valeinis,Dirk van den Berge,Sandra Collette,Laurence Collette,Rolf-Peter Mueller +16 more
TL;DR: After radiosurgery or surgery of a limited number of brain metastases, adjuvant WBRT reduces intracranial relapses and neurologic deaths but fails to improve the duration of functional independence and overall survival.
Journal ArticleDOI
A European Organisation for Research and Treatment of Cancer Phase III Trial of Adjuvant Whole-Brain Radiotherapy Versus Observation in Patients With One to Three Brain Metastases From Solid Tumors After Surgical Resection or Radiosurgery: Quality-of-Life Results
Riccardo Soffietti,Martin Kocher,Ufuk Abacioglu,Salvador Villà,François Fauchon,Brigitta G. Baumert,L. Fariselli,Tzahala Tzuk-Shina,Rolf-Dieter Kortmann,Christian Carrie,Mohamed Ben Hassel,Mauri Kouri,Egils Valeinis,Dirk van den Berge,Rolf P. Mueller,Gloria Tridello,Laurence Collette,Andrew Bottomley +17 more
TL;DR: This study shows that adjuvant WBRT after surgery or radiosurgery of a limited number of brain metastases from solid tumors may negatively impact some aspects of HRQOL, even if these effects are transitory.
Journal ArticleDOI
Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial
René O. Mirimanoff,Thierry Gorlia,Warren P. Mason,Martin J. van den Bent,Rolf-Dieter Kortmann,Barbara Fisher,Michele Reni,Alba A. Brandes,Jüergen Curschmann,Salvador Villà,Gregory Cairncross,Anouk Allgeier,Denis Lacombe,Roger Stupp +13 more
TL;DR: RPA retains its prognostic significance overall as well as in patients receiving RT with or without TMZ for newly diagnosed GBM, particularly in classes III and IV.
Journal ArticleDOI
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial
Almudena Zapatero,A. Guerrero,Xavier Maldonado,Ana Alvarez,Carmen González San Segundo,Maria Angeles Cabeza Rodriguez,Víctor Macías,Agustí Pedro Olive,Francesc Casas,Ana Boladeras,Carmen Martín de Vidales,Maria Luisa Vazquez de la Torre,Salvador Villà,Aitor Perez de la Haza,Felipe A. Calvo +14 more
TL;DR: 5-year biochemical disease-free survival was significantly better among patients receiving long-term androgen deprivation than among those receiving short-term treatment, and 2 years of adjuvant androgens deprivation combined with high-dose radiotherapy improved biochemical control and overall survival in patients with prostate cancer.